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Abstract
A recent analysis of the genetic features of medulloblastoma (MB) suggested classification into distinct subgroups
according to gene expression profiles, including the Wingless signaling pathway–activated group (WNT group), the
Sonic Hedgehog signaling pathway–activated group (SHH group), group 3, and group 4. To classify MB according
to genetic features in practice, we analyzed 74 MBs using representative markers of each group. Based on immuno-
histochemistries (IHC), cytogenetic alterations, and a CTNNB1 mutation study, the patients were divided into the fol-
lowing three groups: cases showing nuclear β-catenin and/or CTNNB1mutation and/ormonosomy 6were included in
the WNT group (14/74, 18.9%); cases expressing GAB1 were included in the SHH group (15/74, 20.2%); cases that
did not show positivity for markers of the WNT or SHH group were included in the non-WNT/SHH group (45/74,
60.6%). Immunoexpression of NPR3 seemed to lack sensitivity for classifying group 3, showing diffuse positivity in only
two cases. KCNA1was not specific to group 4 because it was expressed in all groups. Cases in theWNT group showed
a slightly better survival than those in the SHH or non-WNT/SHH group, although additional cases are required for
statistical significance. Isochromosome17q (P= .002) and the large cell/anaplastic variant (P= .002)were demonstrated
to be poor prognostic indicators in multivariate analysis. The representative IHC and cytogenetic data facilitated the
division of MBs into the WNT and SHH groups; however, more specific markers should be added for the identification
of group 3 and group 4 in practice.
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Introduction
Recent analyses of the genetic features of medulloblastoma (MB) have
suggested classification of MB into four distinct subgroups according
to gene expression profiles [1–4]. As MB exhibits highly variable bio-
logic behavior and a wide histopathologic spectrum, these results could
provide biologic risk stratification and tailored patient treatment.
Data produced by gene expression profiling revealed that MB can
be subdivided into the Wingless signaling pathway–activated group
(WNT group), the Sonic Hedgehog signaling pathway–activated
group (SHH group), and additional two groups, both of which show
neuronal/photoreceptor differentiation (group 3 and group 4) [5]. The
molecular features of each group reflect the distinct developmental
origin of MB and also correlate with clinicopathologic traits [3,5,6].
Briefly, the WNT group often comprises older children and exhibits
a classic histology, nuclear β-catenin expression, CTNNB1 mutation,
and monosomy 6 with a relatively good prognosis. Meanwhile, the
SHH group occurs in infants and young adults and frequently exhibits
a desmoplastic/nodular (D/N) histology, GAB1 expression, PTCH1/
SUFUmutation, andMYCN/GLI2 amplification with an intermediate
prognosis. Group 3 MBs show the worst prognosis, frequently occur-
ring in infants and children. This group exhibits classic or large cell/
anaplastic (LC/A) histology, NPR3 expression, chromosome 7 gain,
chromosome 8 loss, i17q [i(17q)], and MYC amplification in many
cases. Finally, group 4MBs have a similar prognosis to the SHH group,
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having classic or LC/A histology frequently, KCNA1 expression, cyto-
genetic alterations similar to group 3 with chromosome X loss, and
MYCN/CDK6 amplification.
However, these genetic features were shown to be not specific for
each group but overlapped between groups, except a few markers.
Nuclear β-catenin expression, CTNNB1 mutation, and monosomy
6 were found in the WNT group exclusively, and GAB1 immuno-
expression and PTCH1/SUFU mutation were regarded as representa-
tive markers of the SHH group [1,3,7]. For groups 3 and 4, only
expressions of NPR3 and KCNA1, respectively, were suggested to
be specific markers. In addition, immunohistochemistries (IHC) of
YAP1 and filamin A were useful for differentiation of both WNT
and SHH groups from the non-WNT/SHH group [7], and CRX
and GRM8 have been evaluated for classifying groups 3 and 4 [8].
To diagnose and classify MB according to genetic groups in practice,
it is necessary to validate the genetic and IHCmarkers in formalin-fixed
paraffin-embedded (FFPE) tumor tissue. We performed array-based
comparative genomic hybridization (aCGH) with fluorescence in situ
hybridization (FISH), IHC using markers representing each subgroup,
and a CTNNB1 mutation study in FFPE MB tissue. On the basis
of these results, we attempted to divide MB cases into four genetic
groups—WNT, SHH, group 3, and group 4—and to verify the use-
fulness of each marker for diagnostic practice.
Materials and Methods
Patients and Specimens
The FFPE tumor tissue samples of 74 MB patients who were
admitted to the Seoul National University Hospital and Seoul National
University Children’s Hospital from 1999 to 2009 were retrieved from
the pathology archive. Studies were performed with the approval of
the Institutional Review Board, Seoul National University Hospital
(H-1106-039-366). Table 1 summarizes patients’ clinical information.
The mean follow-up period was 45.2 months (range, 3–159 months).
All patients except three were treated with surgical resection and ad-
juvant chemotherapy and radiotherapy. One patient did not receive
both chemotherapy and radiotherapy after surgery because the patient
died before the postoperative therapy, and two patients did not receive
chemotherapy and radiotherapy, respectively.
Histopathologic Review and IHC
Two pathologists (S.-H.P. and H.S.M.) who were unaware of the
clinical data reviewed all slides for histologic subtyping, and FFPE tissue
microarrays (two 2-mm representative cores) were produced for IHC
staining and FISH. MBs were classified as classic, D/N, MB with ex-
tensive nodularity (MBEN), or LC/A variants according to the 2007
World Health Organization (WHO) classification. Cases with a dis-
tinctive biphasic phenotype comprising a pale nondesmoplastic nodular
area and an internodular desmoplastic cellular area were diagnosed as a
D/N variant, and cases with predominant and extended lobular archi-
tecture with neurocytic differentiation were diagnosed as MBEN. A
large cell variant displayed proliferation of discohesive large, round cells
with prominent nucleoli, and an anaplastic variant exhibited marked
nuclear pleomorphism and high mitotic activity. IHC staining of all
74 cases was performed automatically according to the manufacturer’s
protocol, based on a biotin-free polymer detection system. The primary
antibodies used were YAP (1:50; sc-101199; Santa Cruz Biotechnology,
Santa Cruz, CA), GAB1 (1:50; Abcam, Cambridge, MA), filamin A
(1:300; PM6/317; Fitzgerald, Acton, MA), SFRP1 (1:300; Abcam),
DKK1 (1:200; 2A5; Abnova, Taipei, Taiwan), β-catenin (1:200; BD
Biosciences, Franklin Lakes, NJ), NPR3 (1:800; Abcam), and KCNA1
(1:500; Abcam). Positive immunolabeling was defined as uniform
intense nuclear and cytoplasmic (β-catenin, filamin A), cytoplasm, or
cytoplasmic membrane (YAP, GAB1, SFRP1, DKK1, NPR3, KCNA1)
labeling in more than 10% of the tumor area.
Fluorescence In Situ Hybridization
FISH was performed on unstained FFPE array slides of all 74 cases as
described previously using commercially available digoxigenin-labeled
cosmid probes for MYC (8q24.12-q24.13; orange; Vysis, Downers
Grove, IL), CEP8 (8p11.1-q11.1; green; Vysis),MYCN (2p24; orange;
Vysis), CEP2 (2p11.1-q11.1; green; Vysis), LIS1 (17p13.3; orange;
Vysis), RARA (17q21; green; Vysis), and MYB (6q23; aqua; Abbott
Molecular Inc, Des Plaines, IL). After performing aCGH, we con-
firmed the data by FISH on chromosomes 2, 6, 8, and 17. However,
monosomy 6 and i17q were regarded as positive only by FISH in cases
that aCGH was not feasible. Briefly, slides were deparaffinized and
treated with proteinase K, then denatured and treated with prediluted
probes and hybridized overnight. Values for each signal and the ratios
of red/green signals were reported in at least 100 nonoverlapping nuclei
per specimen. Specimens containing either more than 10 signals or
innumerable tight clusters of signals in more than 10% of tumor cells
were consideredMYC orMYCN amplification. Evaluation of chromo-
some 6q loss and alteration of chromosome 17q were defined as de-
scribed previously. Gains of 17q were diagnosed in cases of three or
Table 1. Summarization of Clinical and Histopathologic Features.
No. of Cases (%; N = 74)
Age at diagnosis
Median (range) 8 years (0–35 years)
≤3 years 15 (20.2)
>3 and ≤18 years 51 (68.9)
>18 years 8 (10.8)
Gender
Male 55 (74.3)
Female 19 (25.6)
Histologic variant*
Classic 47 (63.5)
D/N, MBEN (desmoplastic) 16 (21.6)
LC/A 11 (14.8)
Extent of surgery
Gross total resection 36 (48.6)
Near total resection 20 (27.0)
Subtotal resection 15 (20.2)
Partial resection 1 (1.3)
NA† 2
Postoperative chemotherapy and radiotherapy
Both 67 (90.5)
Chemotherapy only 3 (4.0)
Radiotherapy only 1 (1.3)
None 1 (1.3)
NA† 2
Recurrence
Absence 50 (67.5)
Presence 21 (28.3)
NA† 3
Metastasis
Absence 45 (60.8)
Presence 25 (33.7)
NA† 4
Follow-up duration, median (range) 45.2 months (3–159 months)
*D/N indicates desmoplastic/nodular; MBEN, medulloblastoma with extensive nodularity;
LC/A, large cell/anaplastic.
†NA, not applicable.
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more green (17q) signals in >10% of nuclei, and polyploidy cases
were recorded separately. Loss of 17p was diagnosed as one red (17p)
and two or more green (17q) signals in >50% of nuclei.
Gene Sequence Analysis
Slides stained with hematoxylin & eosin (H&E) were reviewed, and
representative tumor areas were marked from which genomic DNA was
extracted.CTNNB1 (exon 3) was amplified by polymerase chain reaction
using previously published primers and directly sequenced using the
ABI Prism 3700 Analyzer (Applied Biosystems, Foster City, CA) [3].
Array-based Comparative Genomic Hybridization
aCGH was feasible in 38 of 74 (51.3%) MBs. After histologic sub-
typing, genomic DNA was extracted from FFPE tissues of 38 cases
and purified using a standard protocol. We performed aCGH analysis
consisting of 4363 human bacterial artificial chromosome clones
(Macrogen, Seoul, South Korea). The experiments were conducted
according to the manufacturer’s protocol [9,10]. Briefly, 2 μg of test
and reference DNA were digested and labeled by random prim-
ing (BioPrime Array CGH Genomic Labeling System; Invitrogen,
Carlsbad, CA) using 3 μl of 1 mM Cy3 or Cy5 dCTP (GeneChem
Inc, Daejeon, Korea). After incubation overnight at 37°C, non-
incorporated fluorescent nucleotides were removed (Purification Mod-
ule; Invitrogen), and the labeled samples were ethanol-precipitated.
Hybridization was performed in slide chambers for 48 hours at
37°C, and the arrays were scanned (GenePix4200A two-color fluo-
rescent scanner; Axon Instruments, Union City, CA) and quantitated
using GenePix software (Axon Instruments).
Data Processing and Statistical Analysis
Frequency plots and tables showing the identified regions of the
copy number errors were generated by analysis of copy number errors.
To detect gains and losses in the aCGH data, the analysis of copy
number error algorithm in CGH-Explorer was used with a P value less
than .01 (false discovery rate of <0.0065) [11]. The threshold for ho-
mozygous deletion and amplification was set to the log2 ratio of ±1.
Kaplan-Meier analysis with the log-rank test, Pearson chi-squared
test, and Fisher exact test were used for univariate analysis, and logistic
regression analysis and Cox proportional hazards model for the sur-
vival analysis were used for multivariate analysis (IBM SPSS Statistics
17.0; SPSS, Inc, Chicago, IL). Results with P values less than .05 were
deemed significant.
Results
Genetic Grouping of MB
The MB series (n = 74) was composed of 47 classic (63.5%),
16 desmoplastic (21.6%; 2 D/N and 14 MBEN variants), and 11 LC/A
(14.8%, 5 large cell and 6 anaplastic variants) variants (Table 1), of
which proportions of histologic variants were slightly higher than those
reported previously [12].
The overall aCGH data revealed several chromosomal aberrations
(gain: 1p/1q, 2, 4p, 5, 7, 9p, 12, 17q, and 18; loss: 3p/3q, 6, 8p/8q,
10q, 11p, 13q, 16q, 17p, 19q, 20p, and X), showing heterogeneous
cytogenetic features of MB. However, unsupervised random hierar-
chical clustering and clustering based on WNT and SHH signaling
pathway–associated genes (KEGG GENES Database; http://www.
genome.jp/kegg/genes.html) failed to divide MBs into the four known
genetic groups (WNT, SHH, group 3, and group 4). Thus, on the basis
of IHC and FISH results and theCTNNB1mutation study, we divided
the 74 MBs into WNT, SHH, and non-WNT/SHH groups. A sum-
mary of the CTNNB1 mutation study, IHC, and cytogenetic results
for all six groups is shown in Table 2 and Figure 1.
WNT group (n = 12). Cases showing monosomy 6 (3/44 cases
by FISH; 5%) and CTNNB1 missense mutation (6/73 cases; 8%) pri-
marily comprised the WNT group (n = 8). The CTNNB1 mutations
in four of six cases were located between codon 34 and codon 38.
However, one case exhibited codon 53 mutation (c. G>A, p.E53K),
and another exhibited codon 60 mutation (c. T>A, p.S60T), both of
which have not been reported in MB previously [13]. The former
case showed diffuse immunoexpression of NPR3. However, we could
not further validate the coexistence of CTNNB1 mutation and NPR3
expression because aCGH was not feasible in this case. Additionally,
we added four cases to the WNT group based on diffuse nuclear
β-catenin expression, of which one case showed neither monosomy 6
nor CTNNB1missense mutation, and CTNNB1 sequencing and FISH
were not feasible in three cases. Of eight cases harboring CTNNB1
mutation and/or monosomy 6, only two showed diffuse nuclear
β-catenin expression.
WNT group tumors exhibited robust immunopositivity for DKK1
(7/12), filamin A (8/12), and YAP (6/12; Figure 2). Foci of positiv-
ity for SFRP1 (3/12) and GAB1 (3/12) were observed, and KCNA1
(7/12) showed scattered positive cells in the tumor area (Figure 2H ).
Of three cases showing GAB1 positivity, one harbored monosomy 6,
and the other two diffusely expressed nuclear β-catenin, comparing
the weak and limited expression of GAB1, which accounted for more
than 10% of the tumor. Eleven cases (11/12) were of the classic type,
and only one case showed LC/A histology.
SHH group (n = 15). Fifteen cases showing GAB1 immunoexpres-
sion without monosomy 6, CTNNB1 mutation, and nuclear β-catenin
expression were included in the SHH group because a PTCH1/SUFU
mutation study was not feasible. Of the IHCmarkers, filaminA (13/15),
YAP (12/15), SFRP1 (11/15), and DKK1 (9/15) were expressed, and
these four IHC markers and GAB1 were positive in the internodular
Table 2. IHC Results in Three Groups of MB.
Group IHC Marker Expression (Case No., %) Case No. (%)
β-Catenin (N )* GAB1 Filamin A YAP DKK1 SFRP1 NPR3 KCNA1
WNT 6 (50) 3 (25) 8 (67) 6 (50) 7 (58) 3 (25) 1 (8) 7 (58) 12 (16)
SHH 0 (0) 15 (100) 13 (87) 12 (80) 9 (57.1) 11 (73) 0 (0) 12 (80) 15 (20)
Non-WNT/SHH 0 (0) 0 (0) 8 (17) 1 (2) 4 (9) 2 (4) 1 (2) 23 (49) 47 (64)
Case No. (%) 6 (8) 18 (24) 29 (39) 19 (26) 20 (27) 16 (22) 2 (3) 42 (57) 74 (100)
*Nuclear expression.
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region in desmoplastic MB cases (Figure 3). Eleven cases were simul-
taneously positive for GAB1, filamin A, YAP, and SFRP1. KCNA1
was positive in 12 cases, in which KCNA1 was diffusely expressed in
neuropil-like matrix regions of desmoplastic MBs (12/15; Figure 3H)
or in some scattered cells, similar to that in WNT tumors. Nuclear
β-catenin and NPR3 expression were negative. Regarding cytogenetic
data, GLI2 amplification (3/11), MYCN amplification (1/14), 10q loss
(3/11), 3q loss (2/11), and X loss (2/11) were observed. Histologically,
desmoplastic MB was observed in seven cases (7/15), the classic type
in five, and the LC/A variant in three.
Non-WNT/SHH group (n = 47). Although only NPR3 and
KCNA1 immunopositivity were used as specific markers for group 3
and group 4, respectively, these two markers did not clearly divide
group 3 and group 4 in the present study. Therefore, the remaining
47 cases were included in the non-WNT/SHH group. Only one case
in this group showed diffuse and strong NPR3 expression. The other
case showing diffuse NPR3 expression was classified into the WNT
group because it harbored the CTNNB1 mutation (c. G>A, p.E53K).
Moreover, KCNA1-expressing cases were found in theWNT and SHH
group tumors as well as the non-WNT/SHH group tumors. The
expression pattern of KCNA1 in the non-WNT/SHH group was dif-
fuse or the same as that of the WNT and SHH group tumors. The
neuropil-like matrix in desmoplastic MBs was diffusely positive for
KCNA1, and in the other histologic subtypes, KCNA1-positive cells
were aggregated or scattered amongKCNA1-negative cells (Figures 2H ,
3H , and 4H ). KCNA1 was expressed in 49% (23/47) of cases, and
other IHC markers including filamin A (8/47), YAP (1/47), DKK1
Figure 2. IHC expression in the WNT group. Diffuse nuclear β-catenin expression (A) and filamin A (B) and YAP (C) expression were
observed. GAB1 expression (D) was negative, except in three cases. DKK1 expression was frequently positive (E), but SFRP1 (F) and
NPR3 (G) expression were mostly negative. KCNA1 (H) showed a patchy infiltration of KCNA1(+) cells among KCNA1(−) cells.
Figure 1. Summary of FISH and aCGH results. Charcoal gray, positive; empty, negative; soft gray, not available.
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(4/47), and SFRP1 (2/47) were expressed in a few cases. Regarding
chromosomal alterations, non-WNT/SHH tumors showed 10q loss
(5/24), 11p loss (5/24), 7q gain (13/24), 8p loss (12/24), and X loss
(2/24, all female cases), amplification of CDK6 (1/24), MYC (1/24),
and MYCN (1/24), and i17q (9/24). Histologically, 31 cases were
classic (31/47, 66%), nine cases were desmoplastic (9/47, 19%), and
seven were LC/A variant (7/47, 15%).
Survival of MB Patients
In univariate analysis, i17q (P = .003) and the LC/A variant (P =
.011) were closely associated with survival. However, genetic subgroups
failed to show statistically significant effects on survival. Children (3 <
age ≤ 18) were more frequent in the non-WNT/SHH group than
in the WNT and SHH groups (P = .007). Classic histology was com-
mon in the WNT group, desmoplastic histology was common in the
SHH group, and the LC/A variant was common in the non-WNT/
SHH group (P = .011). In multivariate analysis, i17q (P = .006)
and the LC/A variant (P = .027) were independently associated with
poor survival.
In Kaplan-Meier survival analyses, patients with i17q had a worse
prognosis than those without i17q (P < .001; Figure 5A), and the LC/
A variant had a worse prognosis than either the classic or desmoplastic
types (P = .004; Figure 5B). Although the WNT group showed a
slightly better outcome than the SHH group and the non-WNT/
SHH group regarding patients who had undergone gross total or near
total resection (Figure 5C ) and children (3 < age ≤ 18) who had
undergone gross total or near total resection (Figure 5D), the differ-
ences were not statistically significant. In a Cox proportional hazards
Figure 3. IHC expression in the SHH group. Cytoplasmic β-catenin expression was positive only in desmoplastic-type nodules (A), while
filamin A (B), YAP (C), and GAB1 (D) expressions were positive in internodular tumor cells. Some cases exhibited DKK1 (E) and SFRP1 (F)
positivity in internodular regions of desmoplastic MBs. NPR3 expression (G) was negative, and KCNA1 expression (H) was positive in
desmoplastic-type nodules.
Figure 4. IHC expression in the non-WNT/SHH group. Expression ofmost of the IHCmarkers, including nuclear β-catenin (A), YAP (C), GAB1
(D), DKK1 (E), and SFRP1 (F), was negative, except in a few cases. Filamin A expression (B) was mostly negative, but eight cases (17%)
were positive. NPR3 expression (G) was diffusely positive in one case, and KCNA1 expression (H) was positive in 23 cases (49%).
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model, i17q (P = .002, hazard ratio = 5.736) and the LC/A variant
(P = .002, hazard ratio = 7.398) were all significant independent
hazards to survival.
Discussion
Tumor classification by distinct gene expression profiling may pro-
vide optimal targeted therapy. However, for routine pathologic eval-
uation using FFPE tissue, it is essential to develop specific markers
that are easily applicable, reproducible, and well correlated with each
molecular subgroup [14]. The present study aimed to investigate the
feasibility of some IHC and cytogenetic markers representing four
genetic groups of MB. Because the results of aCGH could not pro-
vide the gold standard concerning genetic clustering of 74 MBs, we
attempted to validate those markers and classify MBs with limitations.
Moreover, several cytogenetic alterations overlapped between genetic
groups, and IHCmarkers expected to be exclusive to one genetic group
were sometimes expressed in other groups.
Regarding IHC markers, we used nuclear β-catenin and GAB1 in
classifying the WNT and SHH groups, and these two groups were
easily divided without significant overlapping, except three cases that
showed both nuclear β-catenin and GAB1 expression. In one case, the
existence of monosomy 6 was helpful for inclusion in the WNT group
despite GAB1 expression. In the other two cases, β-catenin expression
was intense and diffuse, in contrast to GAB1 expression, which was
relatively weak and limited, although its expression accounted for
more than 10% of the tumors. In addition, we found that DKK1,
SFRP1, filamin A, and YAP immunoexpression could be relatively
well controlled, but the expression levels lacked specificity for each
genetic group. Moreover, each IHC expression profile depended on
specific clones [7]. We used a few more clones for optimal immuno-
expression of these markers; however, we failed to achieve specific
expression, excluding the clones in current use. DKK1 and SFRP1 were
expressed mostly in the WNT and SHH groups; however, SFRP1 was
focally expressed in the WNT group, which harbored the CTNNB1
mutation or expressed nuclear β-catenin. Likewise, DKK1 was
Figure 5. Kaplan-Meier survival curves of the i17q (+) and i17q (−) groups (A), histologic subtypes (B), genetic groups that had undergone
gross total or near total resection (C), and genetic groups comprising only children (3< age≤ 18) (D), who had undergone gross total or near
total resection.
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expressed in the internodular area of desmoplastic SHH group tumors,
which showed GAB1 expression. Negative expression of YAP and
filamin A has been reported to be a marker of non-WNT/SHH group
[7]; however, some cases of non-WNT/SHH group tumors expressed
YAP (2%) and filamin A (17%). We also tested GLI1, CRX, and
GRM8 as markers of the SHH group, group 3, and group 4, re-
spectively; however, we failed to optimally express these markers for
grouping (data not shown).
For classifying groups 3 and 4, KCNA1 and NPR3 were neither
specific nor sensitive markers in the present study. Although this result
is in contrast to previous data [4,15], a recent report by Bien-Willner
et al. supported the low specificity of KCNA1 and NPR3 [16].
KCNA1 lacked specificity as its expression was identified in all sub-
groups, and NPR3 lacked sensitivity and probably specificity, show-
ing expression in only two cases, one of which in the WNT group
harbored the CTNNB1 mutation. Overall, the data suggest that, in
the IHC study, only nuclear β-catenin and GAB1 expression are useful
for differentiating the WNT and SHH groups, respectively, and no
specific marker for classifying groups 3 and 4 is yet available.
In cytogenetic analyses, monosomy 6 was regarded as an indicator
of the WNT group, and no other alterations are known to be specific
to this genetic subgroup. Although 7 gain, 8 loss, and i17q were far
more frequent in non-WNT/SHH tumors, these alterations were found
in a few cases of WNT and SHH tumors. In cases in which aCGH was
feasible, overall cytogenetic alterations, including 3p loss, 10q loss, 11p
loss, and X loss, were identified more frequently in the non-WNT/SHH
group than in the WNT and SHH groups.
Although the overall statistical analyses were more or less limited
due to the small number of cases in each subgroup, a few well-known
prognostic factors repeatedly showed their impact on clinical outcome.
The patients showing i17q and the LC/A histology had a significantly
poorer outcome in multivariate analysis, a finding that was consistent
with previous data [12,17–20]. Regardless of the presence of residual
tumor or disease stage, i17q was an independent negative prognostic
factor in our study. i17q is the most common chromosomal alteration
(25–35%) in childhood MB [19,21], and it is known to be associated
with poor survival, independent of high-risk clinical factors [19]. Both
isolated 17p loss [17,22,23] and isolated 17q gain [24] have shown
a significant association with poor survival; however, these alterations
did not show prognostic impact in our results. In addition, LC/A
histology was shown to have prognostic significance. Although a close
association with MYC or MYCN overexpression has been suggested
[25,26], LC/A histology was reported to be an independent poor
prognostic factor [25]. Because MYC or MYCN amplification was
found in only one case each, the association with the LC/A phenotype
was not validated in our series. Regarding genetic subgroups, theWNT
group showed a better prognosis than the SHH and non-WNT/SHH
groups in children who had undergone gross total or near total resec-
tion; however, a greater number of cases and longer follow-up duration
are required to achieve statistical significance. Of the five patients in
the WNT group who have died (5/12), two were young adults (age =
21 and 22 years, respectively) who died 7 years after the initial surgery.
One pediatric patient who died 1 year after the surgery had i17q, and
in the other two pediatric patients, FISH was not feasible.
Differentiation of tumors of theWNT group from the other groups is
important because the WNT group shows a much more favorable out-
come. On the basis of tests for the CTNNB1 mutation, monosomy 6,
and immunoexpression of nuclear β-catenin and GAB1, we classified
cases into the WNT, SHH, and non-WNT/SHH groups as described
previously [5]. However, the survival analysis failed to show a significant
difference among genetic groups and demonstrated only the prog-
nostic significance of i17q and LC/A histology. In addition, NPR3
and KCNA1 did not appear to be sufficiently sensitive or specific for
genetic grouping, in contrast to previous data. Additional representa-
tive IHC markers are required for classifying groups 3 and 4 tumors
in diagnostic practice.
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